InnobationBio specializes in innovative biotherapy and biomarker development, focusing on enhancing cancer treatment through advanced technologies. Their T-cell therapy aims to rejuvenate cancer patients by utilizing both natural and CAR T cells, which are engineered to target and eliminate cancer cells. Additionally, the company is advancing antibody therapeutics that work in harmony with the body rather than counteracting it, thereby improving treatment efficacy. Their pipeline includes a range of therapeutic programs, such as anti-CD47 CAR T therapeutics and bi-specific CAR-T therapies, which are designed to enhance the immune system's ability to combat cancer.

A significant aspect of InnobationBio's technology is their companion diagnostic biomarker, YN1203, which is designed to predict patient responses to immune checkpoint inhibitors. This biomarker has demonstrated superior predictive power compared to existing tests, showing higher accuracy in identifying responders among non-small cell lung cancer patients. The YN1203 ELISA kit offers a non-invasive method for assessing treatment efficacy in real-time, making it a versatile tool for clinicians. By ensuring patient safety and optimizing treatment strategies, InnobationBio's technologies represent a significant advancement in personalized cancer therapy.

South Korea

InnobationBio Co., Ltd., headquartered in the Republic of Korea, is a biotechnology company having established two major platforms. Its R&D capabilities are utilized to develop antibody and cell immunotherapy for cancer treatment, as well as liquid biopsy-based biomarkers.

InnobationBio

Company Details